PKP2 and arrhythmogenic right ventricular cardiomyopathy: We propose that cardiac AAV9:PKP2 could be a beneficial gene therapy approach to reduce ventricular arrhythmias, slow down adverse right ventricular remodeling, improve heart function, and reduce mortality in ARVC patients with PKP2 mutations.